December 2025 Quarterly Activities Report & Appendix 4C
Filed with ASX · · 9 pages · English
• Cash balance as at 31 December 2025 was $4.7M with an estimated $1.8M1 in R&D tax credits forecast for Q2 2026. • United States Patent and Trademark Office and the European Patent Office have allowed patent applications covering Avecho’s proprietary CBD TPM® soft-gel capsule Melbourne, Australia, 29 January 2026: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or “the Company”) is pleased to p
Avecho Biotechnology Limited on 6ix
Story so far
Earlier from Avecho Biotechnology
- Phase III CBD Clinical Trial Recruitment Update
- AVE Secures US & EU Patent Allowances for CBD Soft-Gel
- September 2025 Quarterly Activities Report & Appendix 4C
- Avecho raises $2.5m via placement
- Appendix 4D and Half-year Financial Report
Later from Avecho Biotechnology
- Annual Report 31 December 2025
- Avecho completes recruitment for Phase III interim analysis
- March 2026 Quarterly Activities Report & Appendix 4C
- Expiry of Listed Options
- Avecho completes treatment for Phase III interim analysis
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology